Idexx Laboratories Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 39.71
Dividend & YieldN/A$ (N/A)
Beta 1.14
Market capitalization 33.87B
Operating cash flow 579.52M
ESG Scores 20.7

Company description

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Sector: Healthcare - Industry: Diagnostics & Research

Financial Ratios
Quick Ratio0.9
Working Capital3.88
Return On Equity1.08
Debt To Equity1.12
Fixed Asset Ratio0.06
Fixed Interest Cover31.27

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -7.88M -10.4M -12.39M 3.68M
Total Cashflows From Investing Activities 138.6M -205.53M -109.38M -292.97M
Net Borrowings -256.04M -10.28M -89.62M 23.5M
Total Cash From Financing Activities -597.8M -286.41M -248.42M -697.41M
Change To Operating Activities -39.73M -34.79M 60.24M -55.15M
Issuance Of Stock 38.2M 36.11M 51.33M 46.56M
Net Income 377.03M 427.72M 581.78M 744.85M
Change In Cash -63.88M -33.47M 293.6M -239.47M
Effect Of Exchange Rate -4.77M -689k 3.33M -4.64M
Total Cash From Operating Activities 400.08M 459.16M 648.06M 755.55M
Depreciation 83.18M 88.01M 96M 104.6M
Change To Account Receivables -18.4M -22.47M -60.72M -33.14M
Other Cashflows From Financing Activities -1.27M -2.53M -6.7M -5.14M
Change To Netincome 31.52M 48.4M 2.05M 43.63M
Capital Expenditures -115.75M -154.97M -106.96M -119.55M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 117.86M 133.19M 141.25M 161.01M
Income Before Tax 457.74M 522.22M 661.99M 902.65M
Net Income 377.03M 427.72M 581.78M 744.85M
Selling General Administrative 632.34M 668.61M 735.27M 796.39M
Gross Profit 1.24B 1.37B 1.57B 1.89B
Ebit 491.33M 563.75M 694.52M 932.03M
Operating Income 491.33M 563.75M 694.52M 932.03M
Interest Expense -34.74M -31.05M -33.12M -29.81M
Income Tax Expense 80.69M 94.43M 79.85M 157.81M
Total Revenue 2.21B 2.41B 2.71B 3.22B
Cost Of Revenue 971.7M 1.04B 1.14B 1.33B
Total Other Income ExpenseNet -36.22M -41.53M -32.54M -29.37M
Net Income From Continuing Ops 377.05M 427.79M 582.13M 744.84M
Net Income Applicable To Common Shares 377.03M 427.72M 581.78M 744.85M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 1.55B 1.65B 1.66B 1.75B
Total Stockholder Equity -9.51M 177.47M 632.09M 689.99M
Other Current Liabilities 67.9M 75.46M 97.62M 83.24M
Total Assets 1.54B 1.83B 2.29B 2.44B
Common Stock 10.51M 10.57M 10.65M 10.69M
Other Current Assets 54.14M 54.81M 59.64M 74.59M
Retained Earnings 1.17B 1.6B 2.18B 2.92B
Treasury Stock -2.33B -2.64B -2.85B -3.62B
Cash 123.79M 90.33M 383.93M 144.45M
Total Current Liabilities 770.44M 725.34M 582.76M 763.58M
Other Stockholder Equity -37.27M -41.72M -49.11M -47.77M
Property, Plant, and Equipment 437.27M 614.45M 646.34M 692.77M
Total Current Assets 654.17M 679.64M 1.06B 955.65M
Net Tangible Assets -265.83M -120.72M 336.2M 231.61M
Net Receivables 272.62M 307.49M 374.74M 425.58M
Accounts Payable 69.53M 72.17M 74.56M 116.14M


Insider Transactions

Here are the insider transactions of stock shares related to Idexx Laboratories Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
MAZELSKY JONATHAN JAYSale at price 433.37 - 435.88 per share.D2022-11-14Chief Executive Officer10.5k
MAZELSKY JONATHAN JAYConversion of Exercise of derivative security at price 62.00 per share.D2022-11-14Chief Executive Officer19k
TURNER KATHY VSale at price 405.21 - 442.05 per share.D2022-11-11Officer13.88k
TURNER KATHY VConversion of Exercise of derivative security at price 178.26 - 206.94 per share.D2022-11-11Officer13.88k
MAZELSKY JONATHAN JAYSale at price 378.60 - 385.01 per share.D2022-11-07Chief Executive Officer13.23k
MAZELSKY JONATHAN JAYConversion of Exercise of derivative security at price 52.00 per share.D2022-11-07Chief Executive Officer24k
JUNIUS DANIEL MStock Award(Grant) at price 364.28 per share.D2022-10-28Director18
AYERS JONATHAN WStock Gift at price 0.00 per share.D2022-09-06Director455k
SMITH MARTIN ALEXANDERD2022-09-01Officer19
MCKEON BRIAN PD2022-08-05Chief Financial Officer192
MAZELSKY JONATHAN JAYD2022-08-05Chief Executive Officer385
JUNIUS DANIEL MStock Award(Grant) at price 399.18 per share.D2022-07-29Director16
MAZELSKY JONATHAN JAYConversion of Exercise of derivative security at price 141.60 per share.D2022-05-20Chief Executive Officer706
SZOSTAK M ANNED2022-05-11Director224
ESSIG STUART MD2022-05-11Director224
AYERS JONATHAN WD2022-05-11Director224
KINGSLEY LAWRENCE DD2022-05-11Director302
VANDEBROEK SOPHIE VD2022-05-11Director224
JUNIUS DANIEL MStock Award(Grant) at price 430.48 per share.D2022-04-29Director15
MAZELSKY JONATHAN JAYStock Gift at price 0.00 per share.D2022-03-04Chief Executive Officer500
TWIGGE GIOVANIConversion of Exercise of derivative security at price 141.60 - 288.78 per share.D2022-02-23Officer2.6k
AYERS JONATHAN WConversion of Exercise of derivative security at price 141.60 per share.D2022-02-18Director706
TURNER KATHY VConversion of Exercise of derivative security at price 67.85 - 141.60 per share.D2022-02-18Officer2.18k
UNDERBERG SHARON EConversion of Exercise of derivative security at price 206.94 per share.D2022-02-17General Counsel483
MCKEON BRIAN PConversion of Exercise of derivative security at price 141.60 per share.D2022-02-16Chief Financial Officer706
AYERS JONATHAN WSale at price 509.70 per share.D2022-02-15Director250
MCKEON BRIAN PD2022-02-14Chief Financial Officer2.08k
POLEWACZYK JAMES FD2022-02-14Officer781
TWIGGE GIOVANID2022-02-14Officer835
MAZELSKY JONATHAN JAYD2022-02-14Chief Executive Officer3.06k
UNDERBERG SHARON ED2022-02-14General Counsel838
TURNER KATHY VD2022-02-14Officer851
LANE MICHAEL JD2022-02-14Officer922
HUNT NIMRATAD2022-02-14Officer675
AYERS JONATHAN WStock Gift at price 0.00 per share.D2022-02-11Director8k
SZOSTAK M ANNEStock Gift at price 0.00 per share.I2022-02-07Director660
JUNIUS DANIEL MStock Award(Grant) at price 489.05 per share.D2022-01-28Director13
ESSIG STUART MStock Award(Grant) at price 489.05 per share.D2022-01-28Director49
COLLINS ASHA S.Stock Award(Grant) at price 489.05 per share.D2022-01-28Director41
CLAFLIN BRUCE LStock Gift at price 0.00 per share.D2021-11-29Director1.56k
POLEWACZYK JAMES FSale at price 633.00 per share.D2021-11-29Officer4.59k
AYERS JONATHAN WStock Gift at price 0.00 per share.D2021-11-19Director6.96k
MCKEON BRIAN PSale at price 620.55 - 621.26 per share.D2021-11-12Chief Financial Officer9.22k
MCKEON BRIAN PConversion of Exercise of derivative security at price 67.85 per share.D2021-11-12Chief Financial Officer9.22k
MCKEON BRIAN PSale at price 621.40 - 629.80 per share.D2021-11-10Chief Financial Officer20k
MCKEON BRIAN PConversion of Exercise of derivative security at price 67.85 per share.D2021-11-10Chief Financial Officer20k
MCKEON BRIAN PSale at price 625.25 - 632.19 per share.D2021-11-09Chief Financial Officer16.31k
MCKEON BRIAN PConversion of Exercise of derivative security at price 67.85 per share.D2021-11-09Chief Financial Officer16.31k
JUNIUS DANIEL MStock Award(Grant) at price 666.14 per share.D2021-10-29Director10
ESSIG STUART MStock Award(Grant) at price 666.14 per share.D2021-10-29Director36
COLLINS ASHA S.Stock Award(Grant) at price 666.14 per share.D2021-10-29Director30

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Idexx Laboratories Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Idexx Laboratories Inc

Here is the result of two systematic investment strategies applied to Idexx Laboratories Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Idexx Laboratories Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Idexx Laboratories Inc:

Idexx Laboratories Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 107.57% on the backtest period.

Performance at glance

Performance

107.57 %

Latent gain

2312.3 $

Invested capital

2149.5 $

Annualized return

26.24 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Idexx Laboratories Inc

This is the result of two momentum investment strategies applied to Idexx Laboratories Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Idexx Laboratories Inc

The following chart shows all the entries opened by the momentum investment system on Idexx Laboratories Inc:

Idexx Laboratories Inc momentum entries
  • The first momentum investment strategy would give 118.97% of return on Idexx Laboratories Inc. That represents 5887.3$ of latent gain with 4948.5$ of employed capital.
  • The second momentum investment strategy would give 84.41% of return on Idexx Laboratories Inc. That represents 2042.29$ of latent gain with 2419.51$ of employed capital.
Performance at glance (1Q Momentum)

Performance

118.97 %

Latent gain

5887.3 $

Invested capital

4948.5 $

Annualized return

35.96 %
Performance at glance (2Q Momentum)

Performance

84.41 %

Latent gain

2042.29 $

Invested capital

2419.51 $

Annualized return

23.32 %

Momentum equity curve on Idexx Laboratories Inc

The following chart shows the equity curve of the two momentum strategies applied to Idexx Laboratories Inc:

Idexx Laboratories Inc momentum equity

Note: the dividends potentially given by Idexx Laboratories Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Idexx Laboratories Inc

The following chart shows the employed capital evolution of the two momentum strategies on Idexx Laboratories Inc since the beginning:

Idexx Laboratories Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Idexx Laboratories Inc

Buy the dip entry openings on Idexx Laboratories Inc

Idexx Laboratories Inc

The performance achieved by the robo-advisor on Idexx Laboratories Inc is 75.52%. That represents 1919.74$ of latent gain with 2542.06$ of employed capital. The following chart shows Idexx Laboratories Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Idexx Laboratories Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

75.52 %

Latent gain

1919.74 $

Invested capital

2542.06 $

Annualized return

35.96 %

Equity curve of the strategy applied to Idexx Laboratories Inc

The following chart shows the result of the investment strategy applied to Idexx Laboratories Inc:

Idexx Laboratories Inc

Note: the dividends potentially given by Idexx Laboratories Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Idexx Laboratories Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Idexx Laboratories Inc:

Idexx Laboratories Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Idexx Laboratories Inc

In this section, I will compare the three previous investment strategies applied to Idexx Laboratories Inc.

Equity curve comparison on Idexx Laboratories Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Idexx Laboratories Inc investment strategy comparison

Employed capital comparison on Idexx Laboratories Inc

Idexx Laboratories Inc investment comparison

Performance comparison on Idexx Laboratories Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 107.57% 2312.3$ 2149.5$ 26.24%
Momentum 1 quarter 118.97% 5887.3$ 4948.5$ 30.82%
Momentum 2 quarters 84.41% 2042.29$ 2419.51$ 23.32%
Non-directional 75.52% 1919.74$ 2542.06$ 35.96%
Annualized return comparison

Automatic investment

26.24 %

Momentum 1Q

23.32 %

Momentum 2Q

23.32 %

Non-directional

35.96 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Idexx Laboratories Inc:

Positive correlations

Most correlated stocks this year

  • Idexx Laboratories Inc

  • Most correlated stocks last 3 months

  • Carrols Restaurant Group Inc
  • Boston Beer Co. Inc - Class A
  • Horizon Therapeutics Plc
  • Blackrock Inc
  • SCOTTISH MORTGAGE INVESTMENT TRUST PLC ORD 5P
  • Papa John`s International Inc
  • Radcom
  • Solaredge Technologies Inc
  • FRANKLIN FTSE TAIWAN ETF
  • Invesco Variable Rate Investment Grade ETF
  • American Century Quality Diversified International
  • Sherwin-Williams Company
  • Amplify Transformational Data Sharing ETF
  • Applied Materials Inc
  • IQ Hedge Market Neutral Tracker ETF
  • Carvana Co. - Class A
  • Principal Millennial GlobalGrowth ETF
  • IQ Hedge Multi-Strategy Tracker ETF
  • Lazydays Holdings Inc
  • CarParts.com Inc
  • IVANHOE MINES LTD
  • BeiGene Ltd
  • McCormick & Co. Inc (Non Voting)
  • WisdomTree PutWrite Strategy Fund
  • S&P Emerging Markets Small Cap ETF
  • iShares MSCI Taiwan ETF
  • SPDR S&P Emerging Asia Pacific ETF
  • First Trust Chindia ETF
  • RH - Class A
  • IFAST
  • ARK Innovation ETF
  • Zillow Group Inc - Class C
  • Zillow Group Inc - Class A
  • AI Powered Equity ETF
  • Lowe`s Cos. Inc
  • Gadsden Dynamic Multi-Asset ETF
  • Biolife Solutions Inc
  • Invesco DWA Consumer Cyclicals Momentum ETF
  • Schwab U.S. Large-Cap Growth ETF
  • First Trust Dorsey Wright Dynamic Focus 5 ETF
  • Fidelity Nasdaq Composite Index ETF
  • First Trust Large Capital Growth AlphaDEX Fund
  • First Trust US Equity Opportunities ETF
  • Vanguard Russell 1000 Growth Index ETF
  • First Trust Technology AlphaDEX Fund
  • First Trust SSI Strategic Convertible Securities E
  • SPDR Bloomberg Convertible Securities ETF
  • UBS AG London Branch
  • ADVISORSHARES DORSEY WRIGHT ADR ETF
  • Idexx Laboratories Inc
  • Nidec Corporation
  • SPDR S&P Kensho Smart Mobility ETF
  • Amplify Online Retail ETF
  • Williams-Sonoma Inc
  • Cadence Design Systems Inc
  • FlexShares Quality Dividend Index Fund
  • FlexShares Quality Dividend Dynamic Index Fund
  • SPDR MSCI Emerging Markets StrategicFactors SM ETF
  • Fidelity MSCI Information Technology Index ETF

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • BAOFENGMODERN

  • Note: The algorithm computes the probability of correlation between Idexx Laboratories Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Idexx Laboratories Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Idexx Laboratories Inc
    Country United States
    City Westbrook
    Address One IDEXX Drive
    Phone 207 556 0300
    Website www.idexx.com
    FullTime employees 10000
    Industry Diagnostics & Research
    Sector Healthcare
    Exchange XNAS
    Ticker IDXX
    Market www.nasdaq.com

    Idexx Laboratories Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 3.6
    Peer Environment Performance 2.2440350877193
    Environment Percentile unknown
    Palm Oil no
    Nuclear no
    Fur Leather no
    GMO no
    Coal no
    Pesticides no
    Animal Testing yes

    Social scores

    Social ESG Factors Scores
    Social Score 7.1
    Peer Social Performance 12.085087719298
    Social Percentile unknown
    Highest Controversy 1
    Peer Highest Controversy Performance 1.9310344827586
    Adult no
    Gambling no
    Alcoholic no
    Tobacco no
    Catholic no
    Controversial Weapons no
    Small Arms no
    Military Contract no
    Peer Count yes

    Related Controversy: Customer IncidentsSociety & Community Incidents


    Governance scores

    Governance ESG Factors Scores
    Governance Score 10.0
    Peer Governance Performance 7.7398245614035
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: 20.7
    Environment Score: 3.6
    Social Score: 7.1
    Governance Score: 10.0

    ESG Performance: AVG_PERF

    Peer Group: Healthcare

    Peer Esg Score Performance: 22.091551724138

    Rating Year: 2022

    Rating Month: 8

    Max Age: 86400

    Percentile: 28